secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001558370-23-017051
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne Q1 GAAP EPS $0.31 (down 44% YoY); CEO Kelderman appointed
--------------------------------------------------------------------

- GAAP diluted EPS $0.31 vs $0.55 prior year; adjusted EPS $0.41 vs $0.45.
- Revenue $276.9M, organic growth +2% (+3% reported).
- ExoDx test volume +49%; GMP proteins revenue +39%; ProteinSimple +9% (ex-China +18%).
- Cash from ops $59.4M, +6% YoY.
- Declared quarterly dividend $0.08/share payable Nov 24; CEO Kim Kelderman effective Feb 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/0001558370-23-017051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/tmb-20231026x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer